Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB2 | P30411 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | QPCT | Q16769 | 1/20 | 0.39 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.36 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9497177 | 0.86 | MCHR1 (0.46) | BDKRB2OPRM1QPCTOPRK1OPRL1 | |
| SCHEMBL201840 | 0.84 | POLB (0.51) | AROPRM1POLBMAPTALDH1A1 | |
| SCHEMBL660327 | 0.83 | ADRB1 (0.43) | OPRM1POLBQPCTALOX5MAPT | |
| SCHEMBL659257 | 0.82 | GAA (0.42) | BDKRB2POLBMAPTALDH1A1MAPK1 | |
| SCHEMBL660567 | 0.78 | MCHR1 (0.57) | OPRM1POLBMAPTOPRK1OPRL1 | |
| SCHEMBL661883 | 0.77 | CRBN (0.53) | POLBMAPTLMNA | |
| SCHEMBL660313 | 0.76 | GPR119 (0.52) | MAPTALDH1A1MCHR1LMNA | |
| SCHEMBL14463379 | 0.75 | MAPT (0.48) | OPRM1ALOX5MAPTOPRL1ALDH1A1 | |
| SCHEMBL17082985 | 0.72 | AR (0.44) | ARPOLBALOX5MAPTALDH1A1 | |
| SCHEMBL17082982 | 0.72 | POLB (0.45) | ARPOLBALOX5MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120045500-A1 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120045500-A1 | NOVEL DIOXO-IMIDAZOLIDINE DERIVATIVES, WHICH INHIBIT THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | SOAT1, SOAT2, ODC1 | BDKRB2 3914/4885AR 3391/4885OPRM1 3412/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.